Stablepharma Secures £2,150,000 to Advance Healthcare Solutions
Revolutionizing Healthcare: Stablepharma Secures £2,150,000 in Funding
In the ever-evolving landscape of biotechnology, Stablepharma has emerged as a leader with a groundbreaking solution that could redefine the future of healthcare. Based in London, UK, this innovative firm has successfully secured a significant €2.5M grant through the prestigious EIC Accelerator Program. Under the visionary leadership of CEO Ozgur Tuncer and Non-Executive Chairman Dr. Steve Chatfield, the company is poised to tackle one of today's most pressing challenges: the distribution and storage of temperature-sensitive medical products. Their cutting-edge technology platform, StablevaX™, transforms approved vaccines, therapeutics, and diagnostics into thermostable products, eliminating the need for refrigeration.
As global demand for reliable healthcare solutions escalates, Stablepharma's innovation addresses critical issues of wastage and inefficiency that have long plagues the cold chain logistics.
With the recent funding of £2,150,000 (GBP), the company is set to push forward with accelerated Phase 1 clinical trials for its flagship candidate, SPVX02—a revolutionary fridge-free tetanus and diphtheria vaccine slated for launch in March 2025. This funding not only highlights the confidence investors have in Stablepharma’s vision but also empowers the firm to potentially save countless lives through improved access to vaccines.
The upcoming trial is expected to wrap up by early Q3 2025, with results anticipated by the end of Q4 2025. This timeline is crucial for stakeholders, as the outcome will pave the way for further investments and partnerships in an industry that is ready for disruption. Moreover, the initiative has garnered additional support from Innovate UK, serving to strengthen the credibility of Stablepharma’s mission. For startup founders and investors alike, this case exemplifies how strategic funding can catalyze transformative innovations in healthcare, making a tangible impact on a global scale.
Key Terms Explained
- EIC Accelerator Program
- A prestigious Europe-based funding opportunity that provides grants to innovative companies, particularly those at an early stage or with high-risk innovations.
- Cold Chain Logistics
- A temperature-controlled supply chain that is used to preserve and extend the shelf life of products, like food, drugs, and vaccines, which need a certain temperature to remain effective.
- Innovate UK
- The UK's innovation agency that provides funding and support for innovative businesses in the country.
Frequently Asked Questions
- How much funding has Stablepharma secured for its healthcare innovation?-Stablepharma has secured £2,150,000 in funding for its innovative healthcare solutions.
- What is the main purpose of the funding Stablepharma has received?+
- What impact could this funding have for investors and the healthcare industry?+
- What does Stablepharma's case show about the role of strategic funding in healthcare innovation?+
- Where is Stablepharma based and who are its leaders?+
They've invested in Stablepharma
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK